DeepMed Research

Quince Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2012-01-01

Employees: 32

Market Cap: $29.8M

Website: http://quincetx.com

Introduction: Quince Therapeutics, Inc.(formerly Cortexyme, Inc.） is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline composed of COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.

Clinical Trials

Open-Label Extension of EryDex Study IEDAT-04-2022

Phase 3

Recruiting

Conditions: Ataxia Telangiectasia

Interventions: Drug: Dexamethasone sodium phosphate

First Posted Date: 2024-10-30

Last Posted Date: 2025-05-01

Lead Sponsor: Quince Therapeutics S.p.A.

Target Recruit Count: 106

Registration Number: NCT06664853

Locations: 🇺🇸
University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence, Los Angeles, California, United States
🇺🇸
The Johns Hopkins Hospital, Division of pediatric allergy and immunology, Baltimore, Maryland, United States
🇺🇸
Biotrial Inc., Newark, New Jersey, United States

and more 16 locations

Evaluate the Neurological Effects of EryDex on Subjects With A-T

Phase 3

Recruiting

Conditions: Ataxia Telangiectasia

Interventions: Drug: Dexamethasone sodium phosphate
Other: Placebo

First Posted Date: 2024-01-05

Last Posted Date: 2025-05-01

Lead Sponsor: Quince Therapeutics S.p.A.

Target Recruit Count: 106

Registration Number: NCT06193200

Locations: 🇺🇸
University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence, Los Angeles, California, United States
🇺🇸
The Johns Hopkins Hospital, Division of pediatric allergy and immunology, Baltimore, Maryland, United States
🇺🇸
Biotrial Inc., Newark, New Jersey, United States

and more 18 locations

Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study

Phase 3

Terminated

Conditions: Ataxia Telangiectasia
Genetic Syndrome

Interventions: Combination Product: EryDex System

First Posted Date: 2018-06-20

Last Posted Date: 2024-10-08

Lead Sponsor: Quince Therapeutics S.p.A.

Target Recruit Count: 104

Registration Number: NCT03563053

Locations: 🇮🇳
Vijaya Health Centre, Department of Neurology, Chennai, Tamil Nadu, India
🇳🇴
Norwegian National Unit for Newborn Screening, Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway
🇬🇧
Nottingham University Hospitals NHS Trust - Queen's Medical Centre, Nottingham, Nottinghamshire, United Kingdom

and more 14 locations

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

Phase 3

Completed

Conditions: Nervous System Disease
Genetic Syndrome

Interventions: Drug: EryDex Low dose DSP
Drug: EryDex High dose DSP
Drug: Pooled Placebo

First Posted Date: 2016-05-12

Last Posted Date: 2024-05-10

Lead Sponsor: Quince Therapeutics S.p.A.

Target Recruit Count: 176

Registration Number: NCT02770807

Locations: 🇮🇳
Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India
🇮🇳
PD Hinduja National Hospital and Medical Research, Mahim, Mumbai, India
🇮🇳
All India Institute of Medical Sciences, New Delhi, India

and more 19 locations

Recovery and Survival of EryDex in Non-patient Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: DSP loaded RBC using EryDex System
Drug: Sham treated RBC using the EryDex System

First Posted Date: 2015-03-05

Last Posted Date: 2016-02-01

Lead Sponsor: Quince Therapeutics S.p.A.

Target Recruit Count: 10

Registration Number: NCT02380924

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

International Ataxia Rating Scale in Younger Patients

Completed

Conditions: Ataxia Telangiectasia

First Posted Date: 2013-09-16

Last Posted Date: 2014-12-31

Lead Sponsor: Quince Therapeutics S.p.A.

Target Recruit Count: 63

Registration Number: NCT01942850

Locations: 🇮🇹
A.O Spedalli Civilli Brescia, Brescia, Italy
🇮🇹
Università La Sapienza, Roma, Italy
🇮🇱
Edmond and Lilly Safra Childrens Hospital Pediatric Unit, Tel Hashomer, Israel

and more 2 locations

EryDex Pharmacokinetics in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)

First Posted Date: 2013-08-20

Last Posted Date: 2015-06-01

Lead Sponsor: Quince Therapeutics S.p.A.

Target Recruit Count: 18

Registration Number: NCT01925859

Locations: 🇺🇸
SNBL Clinical Pharmacology Center, Baltimore, Maryland, United States

Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease

Phase 3

Terminated

Conditions: Crohn's Disease

Interventions: Drug: Dexamethasone

First Posted Date: 2011-01-14

Last Posted Date: 2024-06-03

Lead Sponsor: Quince Therapeutics S.p.A.

Target Recruit Count: 51

Registration Number: NCT01277289

Locations: 🇷🇴
Spitalul Clinic Judetean De Urgenta, Cluj-Napoca, Romania
🇮🇹
Ospedale Careggi, Firenze, Italy
🇮🇹
Policlinico Sant'Orsola, Bologna, Italy

and more 5 locations

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients

Phase 2

Completed

Conditions: Nervous System Disorder
Genetic Syndrome

Interventions: Drug: Dexamethasone

First Posted Date: 2010-12-07

Last Posted Date: 2024-10-10

Lead Sponsor: Quince Therapeutics S.p.A.

Target Recruit Count: 22

Registration Number: NCT01255358

Locations: 🇮🇹
University La Sapienza, Rome, Italy
🇮🇹
Spedali Civili, Brescia, Italy

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy